Lege Artis Medicinae

[TRANSMYOCARDIAL LASER REVASCULARIZATION. FACTS AND QUESTIONS]

SZÉKELY László

OCTOBER 20, 2001

Lege Artis Medicinae - 2001;11(10)

[Transmyocardial laser revascularization (TMLR) is a relatively new technique for the treatment of patients with angina refractory to other medical interventions, such as CABG or PTCA. The laser drills channels through the myocardial wall into the cavity of the ventricle. While the mechanism of action is still debated, clinical data show incentive results suggesting favorable outcome for patients. In the article, the published clinical and experimental data relevant to theoretical mechanisms and clinical results are reviewed.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Small Bowel Ileus of Rare Etiology]

SUGÁR István, ONDREJKA Pál, ISTVÁN Gábor

Lege Artis Medicinae

[ACE Inhibitor for Everyone?]

CZURIGA István

Lege Artis Medicinae

[TEMS]

MATOS Lajos

Lege Artis Medicinae

[Bioterrorism: Anthrax, Smallpox... Rumours and Realities as Seen by a Pediatric Infectologist]

MÉSZNER Zsófia

Lege Artis Medicinae

[PEDIATRIC ONCOLOGY IN HUNGARY IN THE NEW MILLENNIUM]

SCHULER Dezső

[Pediatric malignancies are the most frequent causes of death among 1-15 year old children. These children are treated in 10 pediatric oncology centres in Hungary with therapy based on the same protocols. The author emphasises the importance of late side effects of the therapy, especially the cardiotoxicity, decreased fertility, secondary tumors and the neuropsychologic sequelae. In pediatric oncology, regular checkups of all affected children is the best way for secondary prevention. Molecular genetic studies and minimal residual disease prove to be valuable prognostic factors. New trends of therapy based on better knowledge of molecular biology and immunological characteristics of tumor cells are also mentioned.]

All articles in the issue

Related contents

LAM Extra for General Practicioners

[EFFECT OF BETA BLOCKERS IN HYPERTENSION, ISCHAEMIC HEART DISEASE, HEART FAILURE AND METABOLIC SYNDROME]

BENCZÚR Béla

[Beta-blockers are among the most widely used drugs for the treatment of cardiovascular diseases. In the mid-90’s, these drugs were recommended as first-line therapies of hypertension. With the introduction of new drugs, the list of first-choice drugs has been extended. The results of recently published major hypertension trials, which compared conventional agents (beta blockers and/or diuretics) with newer agents (angiotensin converting enzyme inhibitors, Caantagonists, angiotensin receptor blockers), raised concerns regarding the role of beta blockers in cardiovascular primary prevention. Subsequently, a metaanalysis of 13 trials has shown that compared with other drug types, beta-blocker therapy is less beneficial in patients with hypertension who do not have heart disease. Nevertheless, in cardiovascular indications other than hypertension (acute myocardial infarction, heart failure and arrhythmias), betablockers retain their dominant position.]

Lege Artis Medicinae

[ACE-INHIBITORS IN THE SECONDARY PREVENTION OF CORONARY ARTERY DISEASE]

SÁRSZEGI Zsolt

[The beneficial effects of angiotensin-converting enzyme inhibitors on biochemical and vascular markers have been proven by many experimental studies. Reduction of the angiotensin-II level has a positive effect on oxidative stress, lipid peroxidation, apoptosis, inflammatory and prothrombotic processes. Two large multicentric trials, EUROPA and HOPE, showed that perindopril and ramipril significantly reduce mortality and the risk of both fatal and non-fatal cardiovascular events in patients with atherosclerosis, thereby making them the base drugs of secondary prevention of coronary artery disease.]

Lege Artis Medicinae

[The importance of hormone replacement therapy in primary and secondary cardiovascular prevention]

KANCZ Sándor

[There has been increasing expectation in hormone replacement therapy (HRT) as a potentially useful preventive intervention. Observational studies indicated 50% relative risk reduction on ischaemic heart disease among current HRT users. Unfortunately, this has not been justified by the results of the large scale, prospective, placebo controlled, double blind secondary prevention trials. Even these trials underscored the potential adverse effects of hormone replacement therapy (thromboembolic complications, gall bladder disease). No results of completed primary prevention trials are available for the moment. Based on these data the AHA/ACC Science Advisory of 2001 recommends: HRT should not be recommended for secondary prevention There are insufficient data to suggest that HRT should be initiated for the sole purpose of primary prevention of cardiovascular diseases.]

Lege Artis Medicinae

[Effect of beta blockers in hypertension, ischaemic heart disease, heart failure and metabolic syndrome]

BENCZÚR Béla

[Beta-blockers are among the most widely used drugs for the treatment of cardiovascular diseases. In the mid-90’s, these drugs were recommended as first-line therapies of hypertension. With the introduction of new drugs, the list of first-choice drugs has been extended. The results of recently published major hypertension trials, which compared conventional agents (beta blockers and/or diuretics) with newer agents (angiotensin converting enzyme inhibitors, Caantagonists, angiotensin receptor blockers), raised concerns regarding the role of beta blockers in cardiovascular primary prevention. Subsequently, a metaanalysis of 13 trials has shown that compared with other drug types, beta-blocker therapy is less beneficial in patients with hypertension who do not have heart disease. Nevertheless, in cardiovascular indications other than hypertension (acute myocardial infarction, heart failure and arrhythmias), betablockers retain their dominant position.]

Lege Artis Medicinae

[Secondary prevention of patients with ischaemic heart disease - The reduction of LDL cholesterol level and the regression of atherosclerosis]

BÁRCZI György, MERKELY Béla

[The authors review the options of secondary medical prevention in patients with ischaemic heart disease, stressing the need and safety of using statins. The beneficial effect of statin therapy on cardiovascular morbidity and mortality and the clinical benefit of the greatest possible reduction in LDL cholesterol level are presented. The atherosclerotic plaque regression achieved by a high-intensity statin therapy in the ASTEROID trial is also briefly reviewed.]